Featured News
Glycovax Pharma to Attend BIO International Convention 2025
Pharma Glycovax will participate, from June 16 to 19, 2025, in the BIO International Convention, at the Boston Convention and Exhibition Center, the largest and most comprehensive event for the full ecosystem of biotech with 20,000 industry leaders from across the globe. https://convention.bio.org/bio-2025
Press Releases
Glycovax Pharma commercializes a more affordable CRM197 protein
Montreal, Canada, June 9, 2025 – Glycovax Pharma Inc. has begun large-scale biomanufacturing of the CRM197 protein for use in numerous conjugate vaccines for human and animal vaccines. The National Research Council of Canada (NRC) has developed a unique and highly efficient production system for CRM197. Glycovax has refined its production to meet regulatory requirements…
Media Centre
Looking for Glycovax Pharma in the media assets? The media centre shares news on the Company's products, research and corporate activities.
Media Contact
About Glycovax Pharma
Founded in Montreal, Canada, in 2016, Glycovax Pharma is a biopharmaceutical company specializing in the design and development of semi-synthetic vaccines. With its unique expertise in glycoimmunology, Glycovax Pharma is at the forefront of more effective vaccine solutions, particularly in the fields of viral, bacterial and cancer infections. For more information, visit: www.glycovax.com
Leadership
Discover Glycovax Pharma's leadership team committed to innovation and excellence in vaccine development. Learn more.
Technology
Learn how Glycovax Pharma’s cutting-edge platform of synthetic antigens, linkers, and adjuvants is shaping next-gen vaccines. Explore our technology to see innovation in action. Learn more.